|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0007546,
umls-concept:C0007559,
umls-concept:C0030685,
umls-concept:C0086418,
umls-concept:C0391871,
umls-concept:C0442120,
umls-concept:C0680255,
umls-concept:C1280500,
umls-concept:C1283071,
umls-concept:C1519010,
umls-concept:C1963578
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2004-11-16
|
|
pubmed:abstractText |
Intraperitoneal (IP) cefazolin and ceftazidime are recommended as empiric treatment for peritoneal dialysis (PD)-associated peritonitis. Human peritoneal mesothelial cells (HPMCs) may be affected by high IP cefazolin and ceftazidime concentrations. Peritoneal dialysate cancer antigen-125 (CA-125) appearance rate can be used to measure HPMC damage.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1060-0280
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2035-40
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15536141-Adult,
pubmed-meshheading:15536141-Anti-Bacterial Agents,
pubmed-meshheading:15536141-Biological Markers,
pubmed-meshheading:15536141-CA-125 Antigen,
pubmed-meshheading:15536141-Cefazolin,
pubmed-meshheading:15536141-Ceftazidime,
pubmed-meshheading:15536141-Epithelial Cells,
pubmed-meshheading:15536141-Female,
pubmed-meshheading:15536141-Humans,
pubmed-meshheading:15536141-Injections, Intraperitoneal,
pubmed-meshheading:15536141-Male,
pubmed-meshheading:15536141-Middle Aged,
pubmed-meshheading:15536141-Peritoneal Cavity,
pubmed-meshheading:15536141-Peritoneal Dialysis,
pubmed-meshheading:15536141-Peritonitis,
pubmed-meshheading:15536141-Prospective Studies,
pubmed-meshheading:15536141-Regression Analysis,
pubmed-meshheading:15536141-Time Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125.
|
|
pubmed:affiliation |
School of Pharmacy, University of Missouri, Kansas City, MO, USA. ManleyH@ACP.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
